# A Study to Evaluate the Safety and Pharmacokinetics of BMS-986177 in Participants With End-stage Renal Dysfunction on Chronic Stable Hemodialysis Treatment

> **NCT02902679** · PHASE1 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 6 (actual)

## Conditions studied

- Thrombosis
- Factor XI
- Renal Impairment
- ESRD (End-Stage Renal Disease)

## Interventions

- **DRUG:** BMS-986177

## Key facts

- **NCT ID:** NCT02902679
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11
- **Primary completion:** 2017-06
- **Final completion:** 2017-06
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2017-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02902679

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02902679, "A Study to Evaluate the Safety and Pharmacokinetics of BMS-986177 in Participants With End-stage Renal Dysfunction on Chronic Stable Hemodialysis Treatment". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02902679. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*